The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed ...
Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") of a class action securities ...
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...
Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...
Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.
News Medical on MSN4h
Radiation and immunotherapy help preserve bladders in patients with muscle-invasive bladder cancerPatients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...
Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback